Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

236 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study.
Cooper TM, Cassar J, Eckroth E, Malvar J, Sposto R, Gaynon P, Chang BH, Gore L, August K, Pollard JA, DuBois SG, Silverman LB, Oesterheld J, Gammon G, Magoon D, Annesley C, Brown PA. Cooper TM, et al. Among authors: sposto r. Clin Cancer Res. 2016 Aug 15;22(16):4014-22. doi: 10.1158/1078-0432.CCR-15-1998. Epub 2016 Feb 26. Clin Cancer Res. 2016. PMID: 26920889 Clinical Trial.
Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium.
Messinger Y, Gaynon P, Raetz E, Hutchinson R, Dubois S, Glade-Bender J, Sposto R, van der Giessen J, Eckroth E, Bostrom BC. Messinger Y, et al. Among authors: sposto r. Pediatr Blood Cancer. 2010 Aug;55(2):254-9. doi: 10.1002/pbc.22456. Pediatr Blood Cancer. 2010. PMID: 20582937 Free article. Clinical Trial.
A phase I study of EZN-3042, a novel survivin messenger ribonucleic acid (mRNA) antagonist, administered in combination with chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium.
Raetz EA, Morrison D, Romanos-Sirakis E, Gaynon P, Sposto R, Bhojwani D, Bostrom BC, Brown P, Eckroth E, Cassar J, Malvar J, Buchbinder A, Carroll WL. Raetz EA, et al. Among authors: sposto r. J Pediatr Hematol Oncol. 2014 Aug;36(6):458-63. doi: 10.1097/MPH.0b013e3182a8f58f. J Pediatr Hematol Oncol. 2014. PMID: 24276047 Free PMC article. Clinical Trial.
Improving access to novel agents for childhood leukemia.
Sun W, Gaynon PS, Sposto R, Wayne AS. Sun W, et al. Among authors: sposto r. Cancer. 2015 Jun 15;121(12):1927-36. doi: 10.1002/cncr.29267. Epub 2015 Feb 11. Cancer. 2015. PMID: 25678105 Free PMC article. Review.
A phase 1 study of azacitidine combined with chemotherapy in childhood leukemia: a report from the TACL consortium.
Sun W, Triche T Jr, Malvar J, Gaynon P, Sposto R, Yang X, Bittencourt H, Place AE, Messinger Y, Fraser C, Dalla-Pozza L, Salhia B, Jones P, Wayne AS, Gore L, Cooper TM, Liang G. Sun W, et al. Among authors: sposto r. Blood. 2018 Mar 8;131(10):1145-1148. doi: 10.1182/blood-2017-09-803809. Epub 2018 Jan 16. Blood. 2018. PMID: 29339403 Free PMC article. Clinical Trial. No abstract available.
Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study.
Sun W, Malvar J, Sposto R, Verma A, Wilkes JJ, Dennis R, Heym K, Laetsch TW, Widener M, Rheingold SR, Oesterheld J, Hijiya N, Sulis ML, Huynh V, Place AE, Bittencourt H, Hutchinson R, Messinger Y, Chang B, Matloub Y, Ziegler DS, Gardner R, Cooper T, Ceppi F, Hermiston M, Dalla-Pozza L, Schultz KR, Gaynon P, Wayne AS, Whitlock JA. Sun W, et al. Among authors: sposto r. Leukemia. 2018 Nov;32(11):2316-2325. doi: 10.1038/s41375-018-0094-0. Epub 2018 Mar 15. Leukemia. 2018. PMID: 29728694 Free PMC article.
Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study.
Burke MJ, Kostadinov R, Sposto R, Gore L, Kelley SM, Rabik C, Trepel JB, Lee MJ, Yuno A, Lee S, Bhojwani D, Jeha S, Chang BH, Sulis ML, Hermiston ML, Gaynon P, Huynh V, Verma A, Gardner R, Heym KM, Dennis RM, Ziegler DS, Laetsch TW, Oesterheld JE, Dubois SG, Pollard JA, Glade-Bender J, Cooper TM, Kaplan JA, Farooqi MS, Yoo B, Guest E, Wayne AS, Brown PA. Burke MJ, et al. Among authors: sposto r. Clin Cancer Res. 2020 May 15;26(10):2297-2307. doi: 10.1158/1078-0432.CCR-19-1251. Epub 2020 Jan 22. Clin Cancer Res. 2020. PMID: 31969338 Free PMC article. Clinical Trial.
Temsirolimus combined with cyclophosphamide and etoposide for pediatric patients with relapsed/refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium trial (TACL 2014-001).
Tasian SK, Silverman LB, Whitlock JA, Sposto R, Loftus JP, Schafer ES, Schultz KR, Hutchinson RJ, Gaynon PS, Orgel E, Bateman CM, Cooper TM, Laetsch TW, Sulis ML, Chi YY, Malvar J, Wayne AS, Rheingold SR. Tasian SK, et al. Among authors: sposto r. Haematologica. 2022 Oct 1;107(10):2295-2303. doi: 10.3324/haematol.2021.279520. Haematologica. 2022. PMID: 35112552 Free PMC article. Clinical Trial.
Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium.
Pommert L, Schafer ES, Malvar J, Gossai N, Florendo E, Pulakanti K, Heimbruch K, Stelloh C, Chi YY, Sposto R, Rao S, Huynh VT, Brown P, Chang BH, Colace SI, Hermiston ML, Heym K, Hutchinson RJ, Kaplan JA, Mody R, O'Brien TA, Place AE, Shaw PH, Ziegler DS, Wayne A, Bhojwani D, Burke MJ. Pommert L, et al. Among authors: sposto r. Am J Hematol. 2022 May;97(5):613-622. doi: 10.1002/ajh.26510. Epub 2022 Mar 8. Am J Hematol. 2022. PMID: 35180323 Free PMC article. Clinical Trial.
236 results